KHP Ventures

We are dedicated team of experienced investors who help to enable groundbreaking work by investing in and fostering companies and technologies that advance the future of health. Entrepreneur-friendly strategic investor that speeds access to new healthcare products and services to improve patient care Established by UNC REX Healthcare in 2012 as part of its commitment to innovation Partners with emerging companies throughout North Carolina and the U.S. Leverages the talent and subject matter experts across the UNC REX and UNC Health Care network

We are a venture capital firm specialised in seed investment for innovative early stage companies. BGV generally acts as lead investor. Our team is made up of life science experts and business analysts that can guide life science companies’ development throughout the entire research and development process. BioGeneration Ventures leverages its knowledge gained from working with a diverse network. This includes universities, early stage biotech companies and large pharma. We enable a range of sector-relevant expertise to build and accelerate product development and transform entrepreneurs and their companies to become attractive investment opportunities within the life sciences industry. Our Strategy BioGeneration Ventures (BGV) was launched in 2006. We manage over EUR 250 million across four funds. BGV invests in medical and healthcare innovations that have high potential to positively impact patients. BGV works with an ethos founded in sound novel science. We seek those innovations that have a truly differentiated scientific basis, supported by convincing experimental data. These innovations must be compelling and stand out in the global scientific arena. Only innovations that can address a significant unmet medical need are considered for investment. We aspire to invest in solutions that provide substantial healthcare impact. Progressing a project from discovery to clinical proof-of-concept requires a breadth of experience that founding teams usually do not have from the outset. Through our extensive network and experience we help founders build their companies to extend their capabilities. We guide our portfolio companies along their journey from the scientific discovery to a targeted product development track. Together with the founders, we seeks to shape the companies and define the objectives that enable a successful exit. Our partnerships BGV invests in partnerships with other professional investors in life sciences and has built relationships with various academic institutions (such as Leiden University), venture capital investors in the Netherlands, the EU and the US. Forbion: BGV operates a joint venture partnership with Forbion, a leading European life sciences venture capital fund. Mibiton: Mibiton provides loans to enable promising young life sciences companies to purchase equipment. BGV actively supports the investment activities with BGV Managing Partner Edward van Wezel serving as a member of the board. Our Investors: BGV has a broad investor base comprising private equity/wealth managers, pension funds, academic institutions, regional development funds and private investors.

Through its activities, Technology Ventures facilitates promising inventions to improve the quality of life for patients around the world. The mission of Technology Ventures is to promote the commercial development of Cedars‑Sinai research into products and services that advance healthcare and improve patient wellbeing. Technology Ventures actively seeks industry partners to develop these technologies and works to establish mutually beneficial long‑term relationships.

Since its genesis at the University of Oxford in 2015, Panacea Innovation has partnered with some of the world’s best sci-entrepreneurs, research bodies, universities and corporates to build more than 280 companies that offer cutting-edge solutions - curating a portfolio of more than GBP£300m in value. Panacea Innovation’s venturing activities are delivered through two complementary arms: Panacea Stars - a technology translation, commercialisation and R&D arm - and Panacea Ventures, the investment management one.

Our Ventures team supports the launch of startups based on University of Michigan technologies and research discoveries. We provide a full suite of resources, services and funding to help you launch sustainable, impactful world changing startups. The Ventures team will engage with you from day one to establish clear and executable commercialization, business formation and funding strategies. As your startup project begins to take form we can provide grant funding and investment capital, as well as business know-how, talent resources and connections to a nationwide network of investors. Whether it is helping you find the perfect team member, investment partner or connecting you with service providers, we have you covered.

We are in the age of discovery, seizing a unique moment in time. Every generation experiences a breakthrough that alters the world. Technology has transformed virtually every aspect of our lives, and now it’s healthcare’s turn. aMoon is here to accelerate this transformation. We partner with exceptional entrepreneurs who harness groundbreaking science and technology to transform healthcare. Through aMoon Velocity and aMoon Growth, we invest in early and late-stage companies pursuing disruptive, cutting-edge solutions for high unmet medical needs. We build bridges between our portfolio companies and global tech, finance and medical research hubs to enable entrepreneurs to turn their vision into reality.